Sanofi's R&D group spotlights a big win for BTKi multiple sclerosis drug. But plenty of questions remain
One of Sanofi’s top mid-stage drug prospects — the subject of a recent short attack — is being flagged through to a battery of pivotal Phase III trials after investigators concluded that the drug passed the primary endpoint with flying colors. And that will likely be heralded as a particularly big win by the biotech they licensed it from.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
